drugset
drugset / Trial / NCT03381768

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

NCT03381768 ↗

Phase 1 Completed 8 enrolled Lars Møller Pedersen
NaSingle-groupOpen-labelTreatment

Summary

An open phase-1, first-in-human, clinical trial investigating the safety and immunological effects of peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides in patients with relapsed follicular lymphoma.

Timeline

Start
2017-12-12
Primary completion
2020-02-12
Completion
2020-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IO103 Vaccine 100 ug —
Subject PD-L2 peptide Vaccine 100 ug —

Indications

follicular lymphoma